Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity

Autor(es):Mostrar menos -

Doimo, Nayara T. S. ^[1] ; Zarate-Blades, Carlos R. ^[1] ; Rodrigues, Rodrigo F. ^[1] ; Tefe-Silva, Cristiane ^[2] ; Trotte, Marcele N. S. ^[3] ; Souza, Patricia R. M. ^[1] ; Soares, Luana S. ^[1] ; Rios, Wendy M. ^[1] ; Floriano, Elaine M. ^[2] ; Brandao, Izaira T. ^[1] ; Masson, Ana P. ^[1] ; Coelho, Veronica ^{[4, 5]} ; Ramos, Simone G. ^[2] ; Silva, Celio L. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Biochem & Immunol, Ctr TB Res, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pathol, Sao Paulo - Brazil

^[3] Univ Estado Rio De Janeiro, Vet Med Dept Anat Pathol, Rio De Janeiro - Brazil

^[4] Univ Sao Paulo, Sch Med, Heart Inst InCor, Immunol Lab, Sao Paulo - Brazil

^[5] NIST, Inst Invest Immunol 3, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: HUMAN VACCINES & IMMUNOTHERAPEUTICS; v. 10, n. 5, p. 1238-1243, MAY 2014.
• Citações Web of Science: 2

Resumo

Despite substantial efforts in recent years toward the development of new vaccines and drugs against tuberculosis (TB), success has remained elusive. Immunotherapy of TB with mycobacterial Hsp65 as a DNA vaccine (DNA-hsp65) results in a reduction of systemic bacterial loads and lung tissue damage, but the high homology of Hsp65 with the mammalian protein raises concern that pathological autoimmune responses may also be triggered. We searched for autoimmune responses elicited by DNA-hsp65 immunotherapy in mice chronically infected with TB by evaluating the humoral immune response and comprehensive histopathology using stereology. Cross-reactive antibodies between mycobacterial and mammalian Hsp60/65 were detected; however, no signs of pathological autoimmunity were found up to 60 days after the end of the therapy. (AU)

• Processo FAPESP: 09/06793-7 - Avaliação de resposta autoimune durante a imunoterapia com DNAhsp65 da tuberculose.
• Beneficiário: Nayara Trevisan dos Santos Doimo
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica